Rznomics reports a redesigned self-circularizing RNA platform that improves production efficiency roughly sevenfold and doubles yield relative to the established permuted intron-exon method for large sequences. The advance extends reliable circular RNA manufacturing to constructs approaching 8 kilonucleotides, including the Factor VIII coding sequence. Because circular RNA resists enzymatic degradation, longer-lasting protein expression from fewer doses becomes more feasible for regenerative and cell-based therapies.
Key Points
- Redesigned platform improves circular RNA self-assembly efficiency roughly sevenfold
- Folding site placement determines circularization success in long sequences
- Method doubles efficiency versus permuted intron-exon at 7.8 kilonucleotides
Longevity Analysis
Durability upstream determines dosing burden downstream. RNA that resists enzymatic breakdown produces steadier protein output over longer intervals, reducing the repeated immune provocation and injection frequency that limit current RNA therapeutics. For regenerative applications — clotting factor replacement, engineered cell therapies, tissue repair proteins — the constraint has been manufacturing, not biology, and removing that constraint widens the range of proteins the body can be instructed to make reliably.
Original published by Longevity.Technology, by Kyle Umipig.